Key result
Tirzepatide produced comparable percentage weight loss in Asian and non-Asian adults with obesity without diabetes.
Why the study?
Given ethnic differences in obesity phenotype and cardiometabolic risk, the authors sought to compare the efficacy and safety of tirzepatide between Asian and non-Asian adults without diabetes.
Does tirzepatide reduce body weight similarly in Asian and non-Asian adults with obesity without diabetes?
Meta-Analysis
Does tirzepatide reduce body weight similarly in Asian and non-Asian adults with obesity without diabetes?
Tirzepatide provides comparable relative percentage weight reduction in Asian and non-Asian adults with obesity, though absolute weight loss is greater in non-Asians due to higher baseline weight.
Answers are grounded in this paper and cite their sources.
Supports similar relative tirzepatide efficacy across ethnicities; extends SURMOUNT data to Asian adults with obesity.
INTRODUCTION: Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial weight loss in adults with obesity. Given ethnic differences in obesity phenotype and cardiometabolic risk, this systematic review and meta-analysis compared tirzepatide's efficacy and safety between Asian and non-Asian adults without diabetes. METHODS: This PROSPERO-registered review (CRD420261361351) searched PubMed, Scopus, Web of Science and ClinicalTrials.gov through 15 March 2026. Phase 3 SURMOUNT randomised, placebo-controlled trials were classified as Asian (100% Asian participants) or predominantly non-Asian (< 25% Asian participants). The primary outcome was the percentage change in body weight. Secondary outcomes included absolute weight change, body mass index (BMI), waist circumference, weight loss thresholds (≥ 5%, ≥ 10%, ≥ 15%) and adverse events. Random-effects meta-analyses and meta-regression were performed. Percentage weight loss appeared comparable between Asian (-18.16%) and non-Asian (-17.92%) trials (p = 0.94), but this underpowered comparison cannot confirm equivalence. Absolute weight loss was greater in non-Asians (-23.46 vs. -16.72 kg; p = 0.03), largely reflecting higher baseline weight. Safety profiles were similar, with no statistically significant interactions by ethnic subgroup. CONCLUSIONS: Tirzepatide provides clinically meaningful weight reduction, with broadly similar relative percentage efficacy across Asian and non-Asian trial populations. These exploratory, indirect findings do not establish ethnic equivalence and require confirmation in adequately powered, ethnicity-stratified trials. REGISTRATION: The meta-analysis was registered in PROSPERO under the registration number CRD420261361351. The review protocol summary is available on the PROSPERO website.
No takes yet. Share an insight, caveat, or question.
Kamrul-Hasan et al. (2026) conducted a meta-analysis in Obesity without diabetes. Tirzepatide in Asian adults vs. Tirzepatide in non-Asian adults was evaluated on percentage change in body weight (p=0.94). Tirzepatide produced comparable percentage weight loss in Asian and non-Asian adults with obesity without diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: